Global Yeast Infection Diagnostics Market Report

The global Yeast Infection Diagnostics market is forecasted to grow at a noteworthy CAGR of 6.34% between 2025 and 2033. By 2033, market size is expected to surge to USD 791.87 Million, a substantial rise from the USD 455.39 Million recorded in 2024.

Yeast Infection Diagnostics Market Size and Forecast 2025 to 2033

The Yeast Infection Diagnostics market is experiencing robust growth, driven by several key factors. A significant contributor is the increasing prevalence of yeast infections globally, particularly candidiasis, which affects millions of individuals annually. For instance, the Centers for Disease Control and Prevention (CDC) notes that vaginal candidiasis is a common condition, with about 75% of women experiencing at least one yeast infection in their lifetime. This widespread occurrence directly fuels the demand for accurate and timely diagnostic solutions. Furthermore, heightened awareness among the general population regarding fungal infections and the availability of over-the-counter diagnostic kits are expanding the market reach.

Opportunities within this sector are emerging from advancements in diagnostic technologies, including the development of rapid and point-of-care testing solutions. These innovations offer convenience and quick results, thereby encouraging more individuals to seek testing. Additionally, the growing focus on personalized medicine and the potential for integrating diagnostic tools with telehealth services present avenues for significant market expansion. The continuous evolution of diagnostic methods promises to enhance diagnostic accuracy and accessibility, propelling market progression.

Market Dynamics

Yeast Infection Diagnostics Market Drivers

• Increasing Prevalence of Yeast Infections Worldwide: The rising global incidence of various yeast infections, including vulvovaginal candidiasis, oral thrush, and cutaneous candidiasis, is a primary driver for the diagnostics market. Data from the World Health Organization (WHO) indicates that candidiasis remains a significant public health concern, with recurrent infections posing a substantial burden on healthcare systems. The ease of transmission and the opportunistic nature of these infections, particularly in immunocompromised individuals or those with underlying health conditions like diabetes, contribute to their widespread occurrence. As reported by the National Institutes of Health (NIH), an estimated 1.4 million outpatient visits for vulvovaginal candidiasis occur annually in the United States alone.
• Growing Awareness and Self-Diagnosis Tendencies: There is an observable surge in public awareness regarding the symptoms and implications of yeast infections, largely facilitated by readily accessible health information online and public health campaigns. This enhanced understanding is empowering individuals to recognize symptoms earlier and increasingly seek diagnostic solutions, including over-the-counter testing options. The U.S. Department of Health and Human Services emphasizes the importance of early diagnosis in preventing complications and improving treatment outcomes. Consequently, a significant portion of individuals are now proactively engaging in self-diagnosis using accessible home testing kits before consulting healthcare professionals. This shift towards self-care and preliminary diagnosis significantly broadens the consumer base for yeast infection diagnostic products, thereby driving market expansion.
• Technological Advancements in Diagnostic Methods: The Yeast Infection Diagnostics market is significantly propelled by continuous innovation in diagnostic technologies. Traditional culture-based methods are being progressively supplemented or replaced by more rapid, sensitive, and specific molecular techniques and immunoassay-based tests. The U.S. Food and Drug Administration (FDA) has approved several advanced diagnostic platforms that offer improved turnaround times and higher accuracy for identifying various Candida species. These advancements include PCR-based assays, which can detect fungal DNA with high precision, even in early stages of infection. The development of point-of-care testing (POCT) devices, offering quick results at or near the patient, is particularly transformative, enhancing accessibility and convenience for both patients and healthcare providers.
• Increasing Healthcare Expenditure and Accessibility to Diagnostics: A consistent increase in healthcare expenditure across various economies, particularly in developing regions, is contributing to improved accessibility and affordability of diagnostic services. Governments and private healthcare providers are investing more in diagnostic infrastructure and reimbursement policies, making yeast infection diagnostics more accessible to a wider population. The Centers for Medicare & Medicaid Services (CMS) data illustrates a sustained growth in healthcare spending, a portion of which is channeled towards diagnostic testing. This financial support, coupled with expanding healthcare networks and a rising number of diagnostic laboratories, ensures that more individuals can undergo necessary testing.

Yeast Infection Diagnostics Market Opportunities

• Development of Rapid Point-of-Care (POC) Tests: The demand for rapid and accurate diagnosis of yeast infections at the point of care presents a significant market opportunity. Current diagnostic methods often require laboratory analysis, leading to delays in treatment initiation. The U.S. Centers for Disease Control and Prevention (CDC) highlights the importance of timely diagnosis for effective management of infectious diseases. The development of innovative POC tests that provide results within minutes, without the need for specialized equipment or highly trained personnel, could revolutionize yeast infection diagnosis. Such tests would be particularly beneficial in resource-limited settings and for immediate clinical decision-making, offering enhanced convenience for both patients and healthcare providers and significantly expanding market penetration.
• Integration of Telehealth and Remote Diagnostics: The increasing adoption of telehealth platforms, accelerated by recent global health events, offers a promising avenue for expanding the reach of yeast infection diagnostics. The U.S. Department of Health and Human Services has emphasized the role of telehealth in improving access to care, especially in rural or underserved areas. By integrating diagnostic kits with telehealth consultations, patients could perform self-tests at home and receive professional medical advice remotely. This model reduces the need for in-person clinic visits, enhances patient convenience, and improves adherence to diagnostic procedures. The technological infrastructure supporting telehealth, coupled with a growing comfort level among consumers with remote healthcare services, creates a fertile ground for the growth of remote yeast infection diagnostic solutions.
• Focus on Personalized Medicine and Targeted Therapies: The emergence of personalized medicine offers a substantial opportunity for advanced yeast infection diagnostics. As indicated by the National Institutes of Health (NIH), understanding the specific Candida species responsible for an infection and its antifungal susceptibility profile is crucial for effective treatment. Diagnostic tools that can quickly and accurately identify the causative agent and provide insights into drug resistance patterns will be highly valuable. This tailored approach allows healthcare providers to prescribe more effective and specific antifungal therapies, reducing treatment failures and the development of drug resistance. The shift towards precision medicine creates a demand for sophisticated diagnostic solutions that go beyond basic identification to provide comprehensive genetic and susceptibility information.
• Expansion in Underserved and Developing Regions: Significant opportunities exist for market expansion in underserved regions and developing countries, where access to advanced diagnostic facilities for yeast infections may be limited. The World Health Organization (WHO) continuously works to improve healthcare access in low and middle-income countries. Implementing cost-effective, easy-to-use, and robust diagnostic solutions in these areas can address a substantial unmet need. Public health initiatives aimed at controlling infectious diseases often include provisions for improving diagnostic capabilities. By focusing on affordable and accessible diagnostic technologies, manufacturers can tap into a large, unserved patient population, contributing to global health equity while simultaneously expanding their market footprint.

Yeast Infection Diagnostics Market Restrain & Challenges

• Lack of Awareness and Stigma Associated with Infections: Despite the high prevalence of yeast infections, a significant portion of the global population, particularly in developing regions, lacks adequate awareness about their symptoms, diagnosis, and treatment. The World Health Organization (WHO) notes that health literacy remains a challenge in many communities. Furthermore, societal stigma surrounding reproductive or intimate health issues often discourages individuals from seeking timely medical attention or diagnostic testing. This reluctance can lead to delayed diagnosis, self-medication with inappropriate remedies, and potential complications. Overcoming these cultural and educational barriers is crucial for increasing the uptake of diagnostic services, as the current lack of awareness and persistent stigma act as substantial restraints on market growth.
• Challenges in Sample Collection and Handling: Accurate diagnosis of yeast infections heavily relies on proper sample collection and handling, which can present significant logistical and technical challenges. For instance, the Centers for Disease Control and Prevention (CDC) provides specific guidelines for collecting specimens for fungal diagnostics to ensure optimal sensitivity and specificity. Inadequate or improper collection techniques, such as insufficient sample volume or contamination during collection, can lead to false-negative or false-positive results, compromising diagnostic accuracy. Additionally, maintaining the viability of fungal samples during transportation to laboratories, especially in remote areas or those with limited infrastructure, can be difficult. These challenges necessitate rigorous training for healthcare professionals and robust sample management protocols, adding complexity and potential points of failure in the diagnostic workflow.
• Competition from Over-the-Counter (OTC) Treatments and Self-Medication: The widespread availability and aggressive marketing of over-the-counter (OTC) medications for yeast infections pose a significant challenge to the diagnostics market. Many individuals opt for self-treatment without proper diagnosis, especially for common conditions like vulvovaginal candidiasis, due to convenience, perceived cost-effectiveness, or embarrassment. The U.S. Food and Drug Administration (FDA) regulates the safety and efficacy of OTC products, and their accessibility contributes to this trend. While OTC treatments can be effective for mild, uncomplicated cases, self-diagnosis without confirmation from a diagnostic test can lead to misdiagnosis, ineffective treatment, or masking of more serious underlying conditions.

Current Trends in the Yeast Infection Diagnostics Market

• Shift Towards Molecular Diagnostics: A significant trend in the Yeast Infection Diagnostics market is the growing adoption of molecular diagnostic techniques, such as Polymerase Chain Reaction (PCR) and nucleic acid amplification tests (NAATs). These methods offer superior sensitivity and specificity compared to traditional culture-based approaches, providing faster and more accurate identification of various Candida species, including those that are difficult to culture. The U.S. National Library of Medicine highlights the enhanced performance of molecular methods in detecting fungal pathogens directly from clinical samples. This shift is driven by the need for rapid results to initiate timely and targeted antifungal therapy, especially in cases of severe or recurrent infections. The ongoing development of multiplex PCR assays further enhances this trend by enabling simultaneous detection of multiple pathogens.
• Emergence of Point-of-Care (POC) Testing Devices: The market is witnessing a notable trend towards the development and commercialization of point-of-care (POC) testing devices for yeast infections. These devices are designed to provide rapid diagnostic results at or near the patient's bedside, eliminating the need for extensive laboratory infrastructure and reducing turnaround times. The World Health Organization (WHO) supports the development of POC diagnostics for infectious diseases to improve accessibility and accelerate clinical decision-making. Such devices often utilize lateral flow immunoassays or simple molecular detection methods, making them user-friendly and suitable for use in diverse healthcare settings, including clinics, pharmacies, and even homecare. This trend significantly improves patient convenience and facilitates earlier intervention, driving market growth.
• Integration of Artificial Intelligence (AI) and Machine Learning (ML) in Diagnostics: The application of artificial intelligence (AI) and machine learning (ML) algorithms is an emerging trend within the Yeast Infection Diagnostics market. AI and ML are being utilized to enhance the accuracy and efficiency of microscopic analysis of fungal samples, interpret complex molecular diagnostic data, and even predict antifungal resistance patterns. The U.S. Department of Health and Human Services has recognized the transformative potential of AI in healthcare, including diagnostics. These technologies can process vast amounts of data to identify subtle patterns that may be overlooked by human observation, leading to more precise diagnoses and better patient outcomes. While still in nascent stages for yeast infection diagnostics, the integration of AI and ML holds immense promise for future advancements.
• Development of Non-Invasive Sample Collection Methods: There is an increasing focus on developing non-invasive and patient-friendly sample collection methods for yeast infection diagnostics. Traditional methods often involve uncomfortable or invasive procedures, which can deter patients from seeking testing. Innovations include the use of self-collected vaginal swabs, saliva samples, and even urine samples for certain types of yeast infections. The U.S. National Institutes of Health (NIH) actively funds research into less invasive diagnostic approaches. These non-invasive techniques improve patient comfort and compliance, making diagnostic testing more accessible and appealing. The convenience offered by these methods is expected to significantly boost testing rates, thereby expanding the market for yeast infection diagnostics.

Segmentation Insights

Yeast Infection Diagnostics Market Analysis, By Product

By Product, the market is categorized into Strips, Cassettes, and Panel Test.

• The largest segment in the Yeast Infection Diagnostics market by product is Strips. This leading position can be attributed to several factors, primarily their cost-effectiveness and ease of use, making them highly accessible for both self-testing in homecare settings and preliminary screening in clinics. Strips often serve as a convenient first-line diagnostic tool, providing rapid qualitative results that can indicate the presence of a yeast infection. Their simplicity of design and minimal requirement for specialized equipment make them a preferred choice, especially in regions with limited healthcare infrastructure. The widespread adoption of strips in over-the-counter diagnostic kits further contributes to their dominant market share.
• The fastest-growing segment in the Yeast Infection Diagnostics market by product is also Panel Test. This segment is experiencing rapid growth due to the increasing demand for comprehensive and accurate diagnostic solutions. Panel tests, particularly those utilizing molecular techniques, can simultaneously detect multiple pathogens, including various Candida species and other co-infecting microorganisms, offering a more complete clinical picture. The ability to differentiate between different causes of similar symptoms, as highlighted by the Centers for Disease Control and Prevention (CDC) in their guidelines for sexually transmitted infections, reduces the need for multiple individual tests and improves diagnostic efficiency. The higher precision and broader scope of panel tests are driving their accelerated adoption in clinical laboratories and specialized clinics.

Yeast Infection Diagnostics Market Analysis, By Test Type

By Test Type, the market is categorized into Vaginal PH Test, Nucleic Acid Amplification Testing (NAAT), and Microbiome Test.

• The largest segment in the Yeast Infection Diagnostics market by test type is Vaginal PH Test. This segment's dominance is primarily due to its simplicity, affordability, and immediate results, making it a widely adopted preliminary screening method, particularly in homecare and basic clinical settings. A change in vaginal pH can be indicative of various vaginal conditions, including yeast infections, although it's often used in conjunction with other symptoms for initial assessment. The ease of availability and accessibility of pH test strips or kits as over-the-counter products contribute significantly to its widespread use. As reported by the U.S. Department of Health and Human Services, accessible diagnostic tools play a crucial role in early detection and self-management.
• The fastest-growing segment in the Yeast Infection Diagnostics market by test type is Nucleic Acid Amplification Testing (NAAT). This segment is experiencing rapid growth due to its superior sensitivity, specificity, and ability to detect even low levels of fungal DNA. NAATs, such as PCR-based assays, offer highly accurate identification of Candida species, including those that are difficult to culture or present in mixed infections. The U.S. Centers for Disease Control and Prevention (CDC) often emphasizes the advantages of molecular diagnostics for infectious disease detection due to their high reliability and speed. The growing demand for definitive and rapid diagnostic results, especially in complex or recurrent cases, is driving the accelerated adoption of NAATs in clinical laboratories and specialized diagnostic centers.

Yeast Infection Diagnostics Market Analysis, By Body Part

By Body Part, the market is categorized into Vagina, Penis, Mouth, Nail, Skin Folds.

• The largest segment in the Yeast Infection Diagnostics market by body part is Vagina. This dominance is attributable to the significantly higher incidence and prevalence of vulvovaginal candidiasis (VVC) among women globally. The Centers for Disease Control and Prevention (CDC) reports that VVC is a very common condition, affecting a large percentage of women at some point in their lives, leading to a consistent and substantial demand for diagnostic solutions for this specific area. The frequent recurrence of VVC in many individuals further contributes to the sustained need for diagnostic testing. The widespread awareness and established diagnostic pathways for vaginal yeast infections also underpin its leading market position.
• The fastest-growing segment in the Yeast Infection Diagnostics market by body part is also Nail. This segment is witnessing rapid growth primarily due to the increasing prevalence of onychomycosis, a fungal infection of the nails, and the growing awareness of its impact on aesthetics and overall health. While often considered a cosmetic issue, severe cases can cause pain and discomfort, prompting more individuals to seek diagnosis and treatment. The U.S. National Institutes of Health (NIH) indicates that onychomycosis affects a considerable portion of the adult population. The development of more effective and accessible diagnostic methods for nail infections, such as direct microscopy and molecular tests that can differentiate between various fungal pathogens, is contributing to this accelerated growth as more individuals seek definitive diagnoses.

Yeast Infection Diagnostics Market Analysis, By Indication

By Indication, the market is categorized into Vulvovaginal Candidiasis, Trichomoniasis, Chlamydia, Gonorrhea, Bacterial Vaginosis, and Others.

• The largest segment in the Yeast Infection Diagnostics market by indication is Vulvovaginal Candidiasis. This segment's leading position is directly attributed to the exceptionally high prevalence of this condition among women globally. The World Health Organization (WHO) consistently highlights vulvovaginal candidiasis as one of the most common vaginal infections, affecting a substantial portion of the female population at least once in their lifetime. The recurring nature of this infection in many individuals also contributes to a continuous demand for diagnostic testing. The well-established diagnostic protocols and widespread awareness surrounding vulvovaginal candidiasis further solidify its dominant share within the market.
• The fastest-growing segment in the Yeast Infection Diagnostics market by indication is also Bacterial Vaginosis. This segment is experiencing rapid growth driven by increased awareness, improved diagnostic capabilities, and the recognition of bacterial vaginosis (BV) as a significant contributor to reproductive health issues. While not a yeast infection, BV often presents with similar symptoms, necessitating differential diagnosis. The Centers for Disease Control and Prevention (CDC) reports BV as the most common vaginal infection in women of childbearing age in the United States. The development of accurate and rapid diagnostic tests to distinguish BV from yeast infections and other conditions is crucial for appropriate treatment, driving its accelerated market expansion.

Yeast Infection Diagnostics Market Analysis, By End User

By End User, the market is categorized into Hospitals, Diagnostics Laboratories, Specialty Clinics, and Homecare Settings.

• The largest segment in the Yeast Infection Diagnostics market by end user is Diagnostics Laboratories. This segment holds the largest share due to their central role in processing a high volume of samples requiring specialized equipment and skilled personnel for accurate yeast infection diagnosis. Diagnostic laboratories offer a comprehensive range of tests, including culture-based methods, molecular assays, and susceptibility testing, providing definitive results for complex and atypical cases. The Centers for Disease Control and Prevention (CDC) often collaborates with diagnostic laboratories for disease surveillance and accurate pathogen identification. Their ability to handle diverse sample types and perform advanced analyses makes them an indispensable component of the diagnostic ecosystem, leading to their dominant market position.
• The fastest-growing segment in the Yeast Infection Diagnostics market by end user is Homecare Settings. This segment is experiencing rapid growth driven by the increasing availability of user-friendly over-the-counter diagnostic kits and a growing consumer preference for convenience and privacy. The shift towards self-care and the widespread adoption of telehealth services, as highlighted by the U.S. Department of Health and Human Services, further fuel this growth. Homecare diagnostics allow individuals to perform preliminary tests in the comfort of their homes, reducing the need for clinic visits and providing immediate insights. The continuous innovation in developing accurate and accessible home testing solutions is expected to maintain its accelerated growth trajectory.

Yeast Infection Diagnostics Market Regional Insights

The market has been geographically analysed across five regions, Europe, North America, Asia Pacific, Latin America, and the Middle East & Africa.

• The largest region in the Yeast Infection Diagnostics market is North America. This dominance is primarily attributable to its well-established healthcare infrastructure, high healthcare expenditure, and significant awareness among the population regarding fungal infections. The presence of leading diagnostic technology providers and early adoption of advanced diagnostic methods further bolster its market position. The Centers for Disease Control and Prevention (CDC) and other public health organizations in North America consistently provide guidelines and initiatives that promote accurate and timely diagnosis of infectious diseases, including yeast infections, contributing to the region's leading share in the market.
• The fastest-growing region in the Yeast Infection Diagnostics market is Asia-Pacific. This region is experiencing rapid growth due to several factors, including a large and rapidly growing population, increasing healthcare expenditure, and improving access to diagnostic facilities. The rising prevalence of chronic diseases, such as diabetes, which predispose individuals to yeast infections, also contributes to this accelerated growth. Furthermore, government initiatives aimed at improving public health and infectious disease control, coupled with the rising awareness among the populace, are driving the demand for advanced diagnostic solutions across countries in the Asia-Pacific region, as observed by the World Health Organization (WHO) in its regional health reports.

Yeast Infection Diagnostics Market Competitive Overview

The Yeast Infection Diagnostics market is characterized by a dynamic competitive landscape, with both established players and emerging innovators striving for market share. Companies are increasingly focusing on developing highly accurate, rapid, and user-friendly diagnostic solutions to meet the evolving demands of healthcare providers and patients. The competitive environment is shaped by a continuous drive for technological advancements, including the integration of molecular diagnostics and point-of-care testing capabilities.

Key players are investing heavily in research and development to introduce novel diagnostic platforms that offer enhanced specificity and sensitivity for various Candida species. Furthermore, strategic collaborations and partnerships are common, aimed at expanding product portfolios and geographical reach, particularly in emerging markets. The market also sees competition from readily available over-the-counter options, prompting diagnostic companies to emphasize the superior accuracy and comprehensive nature of professional diagnostic tests.

Leading Market Players in the Yeast Infection Diagnostics Market

• Hologic Inc.: Hologic Inc. is a prominent player in the Yeast Infection Diagnostics market, renowned for its strong focus on women's health and diagnostic solutions. The company offers a diverse portfolio of products that include molecular diagnostic assays capable of detecting various sexually transmitted infections and vaginal infections, including those caused by yeast. Their diagnostic platforms are widely utilized in clinical laboratories globally, known for their high throughput and automation capabilities. Hologic's commitment to innovation is reflected in their continuous development of highly sensitive and specific tests, contributing to improved diagnostic accuracy and patient management. Their strong market presence is supported by extensive research and development efforts and a robust global distribution network, ensuring accessibility of their diagnostic technologies.
• Becton, Dickinson and Company: Becton, Dickinson and Company (BD) is a global medical technology company with a significant presence in the Yeast Infection Diagnostics market, primarily through its diagnostic systems and microbiology solutions. BD offers a comprehensive range of products designed for the identification and susceptibility testing of various microorganisms, including fungi responsible for yeast infections. Their diagnostic instruments and reagents are widely used in clinical laboratories for both routine and specialized testing, providing reliable and efficient results. BD's commitment to advancing healthcare is evident in their ongoing investment in research and development, focusing on integrated diagnostic workflows and innovative solutions that enhance patient care and clinical outcomes worldwide.
• BIOSYNEX SA: BIOSYNEX SA is a key European player in the rapid diagnostics market, offering a range of solutions for infectious diseases, including yeast infections. The company specializes in the development and manufacturing of rapid diagnostic tests (RDTs) that provide quick and accurate results, often at the point of care. Their product portfolio includes various immunoassays and molecular tests designed for easy use and accessibility, catering to both professional healthcare settings and self-testing needs. BIOSYNEX focuses on providing innovative, cost-effective, and user-friendly diagnostic tools that support early detection and effective management of various conditions. Their agile approach to product development and strong regional presence contributes to their competitive standing in the diagnostics landscape.

Top Strategies Followed by Players

• Strategic Product Development and Innovation: A primary strategy adopted by leading players in the Yeast Infection Diagnostics market is the continuous investment in strategic product development and innovation. This involves focusing on creating more accurate, rapid, and user-friendly diagnostic tests, particularly those leveraging advanced molecular technologies and point-of-care capabilities. For instance, the U.S. Food and Drug Administration (FDA) has noted an increase in submissions for novel diagnostic assays offering faster turnaround times and higher specificity. Companies are actively developing multiplex assays that can detect multiple pathogens simultaneously, improving diagnostic efficiency and clinical utility. This emphasis on innovation ensures that players remain at the forefront of technological advancements, providing superior solutions that meet the evolving demands of the healthcare sector and capture greater market share.
• Expansion through Strategic Partnerships and Collaborations: Many key players are pursuing growth through strategic partnerships and collaborations with other diagnostic companies, research institutions, and healthcare providers. These alliances enable companies to expand their product portfolios, access new technologies, and enhance their market reach. For instance, a report by the U.S. Department of Commerce indicates that collaborations in the medical technology sector are on the rise, facilitating shared expertise and market penetration. Such partnerships can involve co-development agreements for novel diagnostic platforms, distribution agreements to enter new geographical markets, or research collaborations to explore new biomarkers for yeast infection diagnosis. These collaborations are crucial for accelerating product development, reducing R&D costs, and gaining a competitive edge in a rapidly evolving market.
• Focus on Market Penetration in Emerging Economies: A significant strategy for market growth involves a concerted effort to penetrate emerging economies. These regions often present substantial untapped market potential due to large populations, increasing healthcare awareness, and improving healthcare infrastructure. The World Health Organization (WHO) consistently highlights the growing healthcare needs in developing countries. Companies are adapting their product offerings to suit the specific needs and economic conditions of these markets, often by introducing more affordable and accessible diagnostic solutions, such as basic rapid tests. Establishing strong distribution networks, providing educational programs for healthcare professionals, and collaborating with local governments are key aspects of this market penetration strategy, aiming to capitalize on the increasing demand for diagnostic services in these rapidly developing regions.

List of Companies Profiled in the Report are:

• Hologic Inc.
• Becton, Dickinson and Company
• Natureland Health
• Stix
• PGYARD
• myLAB Box
• Juno Bio
• Seroflora
• PrivaPath Diagnostics
• NutraBlast
• Rite Aid Corporation
• Home Health (UK) Ltd
• Loyalbody
• Savyon Diagnostics
• Biosynex SA.

Global Yeast Infection Diagnostics Market Report: Scope

List of Segments Covered

This section of the Yeast Infection Diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Strips
• Cassettes
• Panel Test

By Test Type

• Vaginal PH Test
• Nucleic Acid Amplification Testing (NAAT)
• Microbiome Test

By Body Part

• Vagina
• Penis
• Mouth
• Nail
• Skin Folds

By Indication

• Vulvovaginal Candidiasis
• Trichomoniasis
• Chlamydia
• Gonorrhea
• Bacterial Vaginosis
• Others

By End User

• Hospitals
• Diagnostics Laboratories
• Specialty Clinics
• Homecare Settings